A clinical study of co-trimazine in comparison with co-trimoxazole and sulphalene in urinary tract infections.
Co-trimoxazole, co-trimazine and sulphalene were tested in a controlled clinical trial of the treatment of urinary tract infections. Forty-three patients were treated with co-trimoxazole, 41 with co-trimazine, and 21 with sulphalene. During the study, sulphalene was found to be inferior to the other drugs and was excluded from further trials. The clinical efficacy of co-trimoxazole and co-trimazine was equal although the doses of trimethoprim and sulphonamide in co-trimoxazole were much higher than that in co-trimazine. In the latter sulphadiazine was used instead of sulphamethoxazole, the intention being to increase the concentration of active sulphonamide in the urine. Side effects tended to be less frequent in the patients treated with co-trimazine, although not significantly.
D000328:Adult; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D011897:Random Allocation; D013411:Sulfadiazine / Q000009:adverse effects / Q000627:therapeutic use; D013415:Sulfalene / Q000627:therapeutic use; D013420:Sulfamethoxazole / Q000009:adverse effects / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use*; D014295:Trimethoprim / Q000009:adverse effects / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D004338:Drug Combinations; D013449:Sulfonamides; D013411:Sulfadiazine; D014295:Trimethoprim; D013420:Sulfamethoxazole; D013415:Sulfalene